June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
VEGF dosage curve in the aqueous humor after bevacizumab intravitreal injection in patients with neovascular AMD
Author Affiliations & Notes
  • Thiago Cabral
    UNIFESP, Vitoria, Brazil
    Ophthalmology, HSPE/IAMSPE, Sao Paulo, Brazil
  • Julia Polido
    UNIFESP, Vitoria, Brazil
    Ophthalmology, HSPE/IAMSPE, Sao Paulo, Brazil
  • Erika Araki Okuda
    Ophthalmology, HSPE/IAMSPE, Sao Paulo, Brazil
  • Akiyoshi Oshima
    Ophthalmology, HSPE/IAMSPE, Sao Paulo, Brazil
  • Pedro Serracarbassa
    Ophthalmology, HSPE/IAMSPE, Sao Paulo, Brazil
  • Rubens Belfort Jr
    UNIFESP, Vitoria, Brazil
  • Caio Regatieri
    UNIFESP, Vitoria, Brazil
  • Footnotes
    Commercial Relationships Thiago Cabral, None; Julia Polido, None; Erika Okuda, None; Akiyoshi Oshima, None; Pedro Serracarbassa, None; Rubens Belfort Jr, None; Caio Regatieri, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1513. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thiago Cabral, Julia Polido, Erika Araki Okuda, Akiyoshi Oshima, Pedro Serracarbassa, Rubens Belfort Jr, Caio Regatieri; VEGF dosage curve in the aqueous humor after bevacizumab intravitreal injection in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1513. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the concentration of vascular endothelial growth factor (VEGF) in the aqueous humor, before and after intravitreal injection of Bevacizumab in eyes with neovascular age-related macular degeneration (AMD).

 
Methods
 

In this prospective study, 24 eyes of 24 patients with choroidal neovascularization secondary to neovascular AMD were treated with a single intravitreal injection of Bevacizumab (0,05mL, 1,25mg of Avastin). Aqueous humor samples were obtained before the intravitreal injection (baseline), at one week, one month and three months after the treatment. The VEGF concentration in the aqueous humor was measured using an enzyme-linked immunometric assay (Assay Designs® and Stressgen®, Enzo Biochem Inc, Farmingdale, NY). Best corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral domain optical coherence tomography (SD-OCT), and fundoscopy were analyzed at the baseline, one week, one and three months after the treatment. Additionally, a correlation between improvement in the BCVA, CRT and VEGF concentration was investigated.

 
Results
 

A significant increase expression of VEGF was observed in the aqueous humor of eyes with neovascular AMD (mean: 179,71 pg/mL) at the baseline. Furthermore, a significant decrease in the VEGF levels (P<0.001) was observed in all time points after intravitreal injection, comparing with the baseline (1 week - 44.18 pg/mL; 1 month: 56,55 pg/mL; 84,44 pg/mL, P<0.001). One week post treatment, it was observed the highest reduction on the VEGF expression (75.41%). As expected, significant improvement on CRT (P<0,05) was observed after the single bevacizumab treatment (baseline - 420 μm; 1 week - 280,95μm; 1 month - 280,65μm and 3 months: 320μm; P<0.01). The improvement on the CRT was directed correlated with the reduction on the aqueous humor VEGF levels.

 
Conclusions
 

The lowest VEGF concentration in the aqueous humor in eyes with neovascular AMD was observed 1 week after Bevacizumab intravitreal injection. There was a significant increase in the VEGF concentration 3 months after the injection. A significant direct correlation was observed between the decrease on the CRT and VEGF levels. Therefore, the VEGF levels might be a potential marker for the neovascular activity.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×